Compare Alibaba Group (BABA) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alibaba Group vs BioNano Genomics Inc — how do they compare? Alibaba Group trades at $125.84 (market cap $308.93B), while BioNano Genomics Inc trades at $1.24 (market cap $13.66M). The key difference: Alibaba Group is far larger — about 22615.7× BioNano Genomics Inc's market cap, and Alibaba Group pays a 0.82% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BABA | BNGO | |
|---|---|---|
Market Cap | $308.93B | $13.66M |
Volume | 18,069,938 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $189.34 | $4.92 |
52-Week Low | $94.83 | $1.06 |
Enterprise Value | $303.72B | $16.26M |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alibaba (BABA) trades at $124.80, down 5.69% on the day amid ongoing legal pressures and earnings misses. The stock shows bullish technical signals with strong moving average support but faces fundamental headwinds from three consecutive quarterly EPS misses. Revenue growth remains positive at $996.35 billion for 2025, with improved net income margin of 13.05%, though cash flow turned negative at -$97.16 billion due to heavy investing activity.
Despite analyst optimism with 86% buy ratings and $195 consensus target, significant legal risks from multiple class action lawsuits and recent earnings underperformance create near-term uncertainty. The 56% upside to target suggests potential value if legal and operational challenges resolve, but investors face elevated regulatory and execution risks in the Chinese market environment.
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
